STOCK TITAN
  1. Home
  2. Sec-filings
  3. AHCO
  4. [8-K] AdaptHealth Corp. Reports Material Event

AdaptHealth (NASDAQ: AHCO) to redeem $325M 6.125% 2028 notes

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

AdaptHealth Corp. announced that its subsidiary AdaptHealth LLC plans to redeem all outstanding 6.125% Senior Notes due 2028 with an aggregate principal amount of $325,000,000. The notes are expected to be redeemed at 100% of principal plus accrued and unpaid interest up to, but not including, the redemption date.

The redemption is conditioned on receiving sufficient net proceeds from a borrowing under the Issuer’s existing delayed draw term loan facility. The redemption date is expected to be August 1, 2026, with payment of the redemption price expected on the next business day, August 3, 2026, after which interest will no longer accrue on the notes.

Positive

  • None.

Negative

  • None.

Insights

AdaptHealth plans a conditional refinancing of its 2028 notes.

AdaptHealth intends to redeem all outstanding 6.125% Senior Notes due 2028 totaling $325,000,000. The company expects to fund this through a borrowing under its existing delayed draw term loan facility, effectively refinancing one form of debt with another.

The filing states the redemption is fully conditioned on receiving sufficient net proceeds from that term loan. The expected redemption date is August 1, 2026, with payment on August 3, 2026, and interest stops accruing after the redemption date. The overall effect on leverage, interest costs, and covenants depends on the term loan’s detailed terms, which are not described here.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Senior notes principal $325,000,000 Aggregate principal of 6.125% Senior Notes due 2028
Coupon rate 6.125% Interest rate on Senior Notes due 2028
Redemption price basis 100% of principal Plus accrued and unpaid interest to, but not including, redemption date
Expected redemption date August 1, 2026 Date notes are expected to be redeemed, subject to condition
Expected payment date August 3, 2026 Next business day when redemption price payment is expected
6.125% Senior Notes due 2028 financial
"issued a notice of redemption for all of its outstanding 6.125% Senior Notes due 2028"
redemption price financial
"at a redemption price equal to 100% of the aggregate principal amount"
The redemption price is the amount of money a person receives when they sell or redeem a bond or investment before it matures. It’s important because it determines how much you get back and can affect your overall profit or loss on the investment. Think of it like the price you get when returning a gift card early—it's the value you receive at that time.
delayed draw term loan facility financial
"borrowing under its existing delayed draw term loan facility in an aggregate principal amount sufficient"
A delayed draw term loan facility is a committed loan that a borrower can tap in one or more installments at specified future times after meeting agreed conditions, rather than receiving the full amount upfront. For investors it matters because it provides a ready source of cash that can change a company’s financial strength, leverage and interest costs when drawn—similar to having a reserved credit line you can use later, which affects liquidity and the risk profile of the business.
indenture regulatory
"Pursuant to the indenture governing the Notes, payment of the Redemption Price is expected"
An indenture is a legal agreement between a company that borrows money by issuing bonds and the people who buy those bonds. It explains the rules the company must follow, like paying back the money and keeping certain financial promises. This document helps both sides understand their rights and responsibilities.
Emerging growth company regulatory
"Emerging growth company On July 6, 2026, AdaptHealth LLC"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

What debt is AdaptHealth Corp. (AHCO) redeeming in this 8-K?
AdaptHealth’s subsidiary plans to redeem all outstanding 6.125% Senior Notes due 2028 with an aggregate principal amount of $325,000,000. These notes will be repaid at 100% of principal plus accrued and unpaid interest up to the redemption date.

What is the redemption price for AdaptHealth’s 6.125% Senior Notes due 2028?
The redemption price equals 100% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest up to, but not including, the redemption date. After that date, interest on the notes will no longer accrue.

How will AdaptHealth (AHCO) fund the redemption of its 2028 Senior Notes?
The redemption is conditioned on AdaptHealth LLC or its subsidiaries receiving net proceeds from a borrowing under an existing delayed draw term loan facility. Those proceeds must be sufficient to cover the full redemption price of the notes.

When are AdaptHealth’s 6.125% Senior Notes expected to be redeemed?
The notes are expected to be redeemed on August 1, 2026, subject to the funding condition. Payment of the redemption price is expected on the next business day, August 3, 2026, in line with the governing indenture.

What happens to interest on AdaptHealth’s 2028 notes after the redemption date?
Interest on the 6.125% Senior Notes due 2028 will stop accruing from and after the redemption date. Holders receive accrued and unpaid interest only up to, but not including, the redemption date as part of the redemption price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001725255 0001725255 2026-07-06 2026-07-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 6, 2026

 

 

AdaptHealth Corp.

(Exact name of registrant as specified in its charter)

 

Delaware  001-38399  82-3677704
(State or other jurisdiction of
incorporation)		  (Commission File Number)  (IRS Employer Identification No.)

 

555 East North Lane, Suite 5075

Conshohocken, PA

   19428
(Address of principal executive offices)   (Zip Code)
     
(610) 424-4515

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading 
Symbol(s)		   Name of each exchange on which
registered
Common Stock, par value $0.0001 per share   AHCO   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.  

 

On July 6, 2026, AdaptHealth LLC (the “Issuer”), an indirect wholly-owned subsidiary of AdaptHealth Corp. (the “Company”), issued a notice of redemption for all of its outstanding 6.125% Senior Notes due 2028 (the “Notes”) in an aggregate principal amount of $325,000,000 (the “Redemption”), at a redemption price equal to 100% of the aggregate principal amount of the Notes to be redeemed, plus accrued and unpaid interest on such Notes to, but not including, the redemption date (the “Redemption Price”). The Redemption will be conditioned upon receipt by the Issuer or any of its subsidiaries of the net proceeds of a borrowing under its existing delayed draw term loan facility in an aggregate principal amount sufficient to pay the Redemption Price (the “Redemption Condition”). The date of redemption is expected to be August 1, 2026 (the “Redemption Date”), subject to the satisfaction of the Redemption Condition. Pursuant to the indenture governing the Notes, payment of the Redemption Price is expected to occur on the next succeeding business day following the Redemption Date, which is August 3, 2026, and no interest will accrue for the period from and after the Redemption Date.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: July 7, 2026

 

AdaptHealth Corp.  
   
By: /s/ Jason Clemens  
  Name: Jason Clemens  
  Title: Chief Financial Officer  

  

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents